Funding IssuesCJS funding gaps remain a key headwind, affecting Sublocade sales and contributing to a 38% decline in the CJS market.
Generic CompetitionA 5th generic from Teva has not yet reached the market, indicating increasing generic pricing pressure.
Market ConfidenceAnalyst recognizes the need to rebuild market confidence after two profit warnings in FY24, with a target price reduced to 1,110p from 1,400p.